Theranostics and Targeted Radiopharmaceuticals: Nuclear Medicine's Commercial Breakthrough

Theranostics, the combination of diagnostic imaging and targeted radionuclide therapy using the same molecular targeting vector, has entered its commercial inflection phase following the approval and market launch of Novartis' Lutathera for neuroendocrine tumours in 2017 and Pluvicto (lutetium-177 PSMA-617) for metastatic castration-resistant prostate cancer in 2022. These approvals validated the theranostic commercial model in oncology and triggered a capital investment cycle in radiopharmaceutical development, manufacturing infrastructure, and clinical delivery that is now producing a pipeline of new targeting agents, therapeutic radionuclides, and clinical indications that is broader and better capitalised than at any prior point in the history of nuclear medicine. The commercial opportunity is substantial: targeted radiopharmaceuticals offer a treatment modality with differentiated mechanism-of-action from conventional chemotherapy, immunotherapy, and targeted therapy that can address patient populations with limited alternative treatment options, commanding premium pricing and demonstrating health technology assessment value that supports reimbursement in major markets.

Lutetium-177 Theranostics: The Established Commercial Platform

Lutetium-177 is the dominant therapeutic radionuclide in current commercial theranostic products, chosen for its beta-particle emission characteristics that deliver therapeutic radiation doses to targeted tumour cells while limiting dose to surrounding healthy tissue, its manageable half-life of approximately 6.6 days that facilitates manufacturing and clinical logistics, and the GMP production infrastructure that has been established at commercial scale by isotope producers including ITG (Isotope Technologies Garching), NorthStar Medical Radioisotopes, and Nuvalis. Pluvicto's commercial launch in metastatic castration-resistant prostate cancer has been constrained by manufacturing capacity limitations at Novartis' Millburn facility, creating a significant demand-supply gap in a large patient population that created both a commercial imperative for Novartis to expand production and an opportunity for competing Lu-177 PSMA therapeutic products from Bayer (BAY 2315179), Point Biopharma, and RadioMedix to advance through clinical development toward regulatory approval.

The PSMA theranostic model, using gallium-68 or fluorine-18 PSMA PET imaging to identify patients with PSMA-expressing prostate cancer who are likely to respond to Lu-177 PSMA therapy, exemplifies the companion diagnostics integration that theranostics requires and that distinguishes it from conventional oncology drug development. The diagnostic imaging component is not merely a companion test but the same molecular targeting mechanism applied with a diagnostic radiolabel rather than a therapeutic radionuclide, creating a clinical workflow where imaging confirms target expression, defines the patient population likely to benefit, and can be used to monitor therapeutic response after treatment. This integrated diagnostic-therapeutic model has significant health technology assessment advantages, as the ability to prospectively identify responding patient populations through imaging improves the clinical benefit-to-risk profile of theranostic treatments and strengthens the value case for payer reimbursement relative to treatments without patient selection biomarkers.

Next-Generation Radionuclides: Alpha Emitters and New Targeting Approaches

Actinium-225 and bismuth-213 alpha-emitting radionuclides represent the next generation of therapeutic radionuclides beyond the established lutetium-177 and yttrium-90 beta emitters, offering shorter path length and higher linear energy transfer that delivers more concentrated radiation to individual tumour cells while reducing dose to surrounding normal tissue. The higher radiobiological effectiveness of alpha particles relative to beta particles creates potential clinical advantages in radioresistant tumour types and in micrometastatic disease where beta emitter path length limitations reduce efficacy, and actinium-225 conjugated to PSMA targeting vectors (actinium-225 PSMA-617, developed by Fusion Pharmaceuticals, acquired by AstraZeneca) is in advanced clinical development with Phase III data expected that could establish alpha-particle theranostics as a new standard of care in prostate cancer beyond the progression stage addressed by lutetium-177 Pluvicto.

The supply constraint for actinium-225 is a significant limiting factor for the commercial development of alpha-emitting theranostics, as the primary production pathway using uranium-233 decay is limited by the availability of legacy uranium-233 stockpiles from nuclear weapons programme residues, and alternative production through proton or neutron irradiation of radium-226 targets is under development at accelerator facilities including TRIUMF in Canada, ORNL in the US, and research reactors in Europe. The investment being made in actinium-225 production infrastructure, including both legacy supply chain development and new accelerator-based production, is a necessary precondition for the commercial scale of alpha-emitting theranostic products that Phase III clinical success will require, and the companies that secure long-term actinium-225 supply agreements ahead of commercial approval are building supply chain positions that will be difficult for later entrants to replicate given the constrained production infrastructure.

Radiopharmaceutical Manufacturing Infrastructure and GMP Logistics

The manufacturing and clinical delivery logistics of radiopharmaceuticals present operational challenges that distinguish this drug category from conventional small molecule and biologic pharmaceuticals. Short-lived radionuclides require production, formulation, quality testing, and delivery to clinical sites within defined time windows that impose geographic constraints on the production-to-treatment supply chain, requiring either distributed manufacturing at or near clinical sites or rapid logistics infrastructure that can deliver product within the radionuclide half-life window. Novartis' investment in multiple Pluvicto manufacturing sites globally, NorthStar Medical Radioisotopes' expanded lutetium-177 production infrastructure, and the development of regional radiopharmaceutical production hubs by contract manufacturers including PharmaLogic, PETNET Solutions, and RayzeBio represent the manufacturing infrastructure buildout that the commercial radiopharmaceutical pipeline requires.

Hospital and cancer centre infrastructure investment in hot labs, radiation safety infrastructure, and nuclear medicine physician capacity is a clinical delivery constraint that limits theranostic treatment adoption even when approved products are available and reimbursed. The Society of Nuclear Medicine and Molecular Imaging and academic medical centres are investing in training programmes and site qualification processes that expand the number of institutions qualified to administer theranostic treatments, but the capital investment in radiation safety infrastructure and the physician training time required to qualify new theranostic treatment sites create a ramp curve that limits near-term patient access to theranostic therapies in markets where nuclear medicine infrastructure is underdeveloped relative to treatment demand.

Pipeline Breadth and Indication Expansion

The theranostic development pipeline extends well beyond prostate cancer and neuroendocrine tumours into breast cancer, lung cancer, colorectal cancer, haematologic malignancies, and glioblastoma through a range of targeting vectors that identify tumour-specific surface antigens, receptors, and metabolic pathways accessible to radiolabelled small molecules, peptides, and antibodies. HER2-targeted radiopharmaceuticals, FAP (fibroblast activation protein) targeting agents active across multiple solid tumour types, integrin-targeting peptides for angiogenesis imaging and therapy, and CXCR4-targeting agents for haematologic malignancy are among the targeting approaches in clinical development that could expand the addressable patient population for theranostic treatments significantly beyond the established PSMA and SSTR2 indications. The pipeline diversity reduces the clinical development risk of the theranostics category as a whole, as commercial success is not dependent on any single targeting approach or tumour indication but on the overall performance of a broad portfolio of agents addressing different molecular targets across multiple cancer types.

Combination therapy strategies that pair theranostic treatments with immunotherapy, DNA damage response inhibitors, or conventional chemotherapy are showing early clinical signals of synergistic activity that could expand theranostic efficacy beyond the patient populations responding to monotherapy. The radiation-induced immunogenic cell death that radionuclide therapy produces in tumour tissue may sensitise tumours to subsequent immunotherapy by exposing tumour antigens that stimulate anti-tumour immune responses, providing a biological rationale for theranostic-immunotherapy combinations that multiple clinical programmes are investigating. If combination therapy strategies demonstrate meaningful clinical benefit beyond monotherapy, the addressable patient population and revenue potential of approved theranostic products could expand significantly, as combination indications would reach patients with disease characteristics that limit monotherapy response while potentially demonstrating superior outcomes in populations that already respond to monotherapy.

Top 10 Companies in Theranostics and Targeted Radiopharmaceutical Oncology

1. Novartis Oncology -- Owner of Lutathera (Lu-177 DOTATATE) and Pluvicto (Lu-177 PSMA-617), the two commercially approved theranostic products defining the current radiopharmaceutical oncology market, with ongoing manufacturing expansion and pipeline development.
2. AstraZeneca (Fusion Pharmaceuticals) -- AstraZeneca's radiopharmaceutical oncology programme through Fusion Pharmaceuticals acquisition, with actinium-225 PSMA-617 and other alpha-emitting theranostic candidates in clinical development across multiple oncology indications.
3. Bayer -- Radiopharmaceutical oncology developer with Xofigo (radium-223) established in bone-metastatic prostate cancer and BAY 2315179 Lu-177 PSMA therapeutic in clinical development, targeting PSMA-positive prostate cancer market.
4. Point Biopharma (Eli Lilly) -- Radiopharmaceutical company acquired by Eli Lilly with PNT2002 Lu-177 PSMA therapeutic and manufacturing facilities in Indianapolis, contributing to Lilly's radiopharmaceutical oncology portfolio development.
5. RayzeBio (Bristol-Myers Squibb) -- Actinium-225 radiopharmaceutical company acquired by BMS, with RYZ101 actinium-225 DOTATATE for SSTR-expressing tumours in Phase III development and actinium-225 manufacturing infrastructure investment.
6. Lantheus Holdings -- Radiopharmaceutical imaging company with PYLARIFY fluorine-18 PSMA PET agent and DEFINITY ultrasound contrast, plus theranostic pipeline with MK-6240 tau imaging and PYLARIFY AI digital health software.
7. Curium Pharma -- Global nuclear medicine product manufacturer and distributor with PET and SPECT radiopharmaceutical production network and growing theranostic product development and manufacturing capabilities.
8. Aktis Oncology -- Radiopharmaceutical company with mini-protein targeting approach enabling novel tumour antigen targeting for radiopharmaceutical therapeutics across solid tumour indications with limited existing theranostic options.
9. NorthStar Medical Radioisotopes -- US producer of no-carrier-added lutetium-177 and other medical radioisotopes, investing in domestic production infrastructure to reduce US dependency on European isotope supply for commercial radiopharmaceutical manufacturing.
10. SOFIE Biosciences -- Radiopharmaceutical development and manufacturing company with AI-assisted automated synthesis technology and Alzheimer's disease tau imaging pipeline alongside oncology radiopharmaceutical development programmes.